Clinical Trial Update: Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating selegiline in combination with docetaxel for metastatic castration-resistant prostate cancer; current status and results not p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Prostate
• Castration-resistant Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Selegiline (selegiline)

Snippet

Sponsor: László Mangel | Conditions: Metastatic Castration-resistant Prostate Cancer, Adenocarcinoma of the Prostate | Phase 2 | Status: UNKNOWN